MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders

Imported from official source

Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA.

This version

Version
1 of 1
Recorded
October 30, 2026 10:00
Change
Initial
Content hash
f045e49fa5993b2a6262768e6bc23077
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.